Antibodies against novel PD1 isoforms and uses thereof
US11236144B2 · kind B2 · utility
0Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 9, 2018 |
| Grant date | Feb 1, 2022 |
| Priority date | — |
| Expiry date | Sep 12, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains to antibodies against a novel isoform of human PD1 protein (Δ42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against Δ42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against Δ42PD1 are monoclonal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.